Pharmacy Drugs
Recent Posts
- EPIX Pharmaceuticals Announces FDA Approval Of A Physician-Sponsored IND For Fourth 6-month Open Label Extension Of PRX-03140 For Alzheimer’s Disease
- Miriam Hospital Researcher Receives More Than $12 Million To Study Weight Control
- Novel HIV Drug To Be Studied In Cell Cultures And Patients
- ISCTM Meeting Discusses Clinical And Regulatory Aspects Of Using Adaptive Designs In Clinical Trials For Central Nervous System Drug Approvals
- Evaluation Of The Cost Effectiveness Of Implantable Blood Pressure Device
Random Posts
- FDA Updates Warning for Pregnant Women on Antiepileptic Drugs
- DIA 45th Annual Meeting Features Sessions Highlighting Wyeth V. Levine And Pandemic Influenza
- National Alert System Launches To Prevent Deadly Medication Errors
- NOXXON Announces Initiation Of First-in-Human Clinical Trial With Hematopoietic Stem Cell Mobilizing Spiegelmer(R) NOX-A12
- Premier Healthcare Alliance Acquires Phase 2 Consulting To Expand Its Performance Improvement Offerings To Its Member Hospitals Nationwide
- Contamination Forces Recall of Hand Sanitizers
- Poster Submissions Invited For PAC - Pharmaceutical Society Of Australia
- Cardiologist Urges People To Get Informed About Angioplasty
- Old Drugs Combine to Produce New Weight Loss Benefit
- NPA Welcomes Timely Reminder On Supply Chain Obligations
Pharmacy Union Concerns Unfounded
Posted by: admin in Pharmacy Drugs on July 21st, 2009
Concerns raised by the Pharmacists’ Division of the Association of Professional
Engineers, Scientists and Managers, Australia over employees being ‘left out’ of
negotiations for the Fifth Community Pharmacy Agreement were unfounded, the
Pharmaceutical Society of Australia said today.
President of the PSA, Warwick Plunkett, said the concerns were raised to stimulate a
response from employee pharmacists on issues to be discussed in the CPA
negotiations.
“But these comments are well off target and display a lack of understanding of the CPA
process and other initiatives seeking to promote pharmacists’ expertise in delivering
health policy priorities,” Mr Plunkett said.
“The Community Pharmacy Agreement is only about community pharmacy-based
services and their remuneration.
“Services that should be funded by government and delivered outside of community
pharmacy need to be the subject of a separate agreement with the profession.”
Mr Plunkett said the PSA, with a membership covering 75 per cent of all practicing
pharmacists including employers and employees, was well represented in the
negotiating process and was well placed to look after the interests of employee
pharmacists in the CPA.
“Of course PSA would welcome any direct ideas or comments from all parts of its
membership to guide it on stances to be taken during the negotiations,” he said.
Responding to APESMA concerns over the future direction of pharmacy, Mr Plunkett
said: “PSA agrees that Government should be, and no doubt is, having dialogue with
the other major pharmacy organisations on issues affecting the profession but not on
those issues relevant to CPA.
“The future direction of Pharmacy is the subject of a Green and White Paper process
recently initiated by PSA and which will include input from all sectors of pharmacy
during its development.
“Professional services relating to Primary Health Care and Preventive Health Care
delivery by community pharmacies will be put forward in the negotiations for CPA5 but
could be subject to attracting funding and support from other areas.”
Source
Pharmaceutical Society of Australia